ReviewInternational journal of obesity (2005)2025
What is the pipeline for future medications for obesity?
Review in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240246 (Effect of a Dietary Supplement), which is not on this map. Cited by 144 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response
Who cites it
144 citing papers in PubMed, 6 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Weight regain after cessation of medication for weight management: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2026Pooled it
- The effect of berberine on obesity indices: a systematic review and meta-analysis.International journal of obesity (2005) · 2026Pooled it
- GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- Beneficial effects of ginger on prevention of obesity through Modulation of gut microbiota.Journal of health, population, and nutrition · 2025Pooled it
- The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.International journal of clinical pharmacy · 2024Pooled it
- Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.The Journal of clinical endocrinology and metabolism · 2026Trial
- Lost and not found: randomized controlled trial of cognitive behavioral therapy for weight-loss in patients with chronic kidney disease.Journal of behavioral medicine · 2025Trial
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/mDiabetes, obesity & metabolism · 2025Trial
- Exerkines in precision management of metabolic diseases.Chinese medical journal · 2026Review
- Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Future GLP-1 receptor co-agonists and their cardiac effects.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries.Diabetes, obesity & metabolism · 2026Article
- Review
- Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.Journal of managed care & specialty pharmacy · 2026Article
- Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.Reviews in endocrine & metabolic disorders · 2026Review
- Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.Contemporary clinical trials communications · 2026Article
- Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.The Journal of international medical research · 2026Article
- Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.JCEM case reports · 2026Article
- Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.Diabetes, obesity & metabolism · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.